Dawaa Reference

chronic

Silicosis

Treatment options, dosing, cautions and Egyptian brands from the shipped Dawaa Reference card.

Evidence status

Checked against the sources named below

Sources5 sources

American Thoracic Society: Adverse Effects of Crystalline Silica Exposure (1997) · WHO Framework for Collaborative Action on Tuberculosis and Comorbidities 2022 · Egyptian MOH National Tuberculosis Control Program 2022 · StatPearls: Silicosis (NCBI Bookshelf NBK594245), Treatment and Management · Silicosis - disease-level clinical article (silicosis-full.txt)

Verified against2 documents
  • StatPearls: Silicosis (NCBI Bookshelf NBK594245), Treatment and Management
  • Silicosis - disease-level clinical article (silicosis-full.txt)

Verified date2026-08

Presentation reference

Is it this?

Reference only, to read alongside your own examination.

Symptoms — what the patient reports (3)

  • In the fast-onset form, breathlessness, chest pain with breathing, cough, fever, tiredness, and weight loss appear within weeks to a few years of heavy dust exposure [breathlessness · chest pain · cough · fatigue · fever · weight loss]
  • The common, slow-onset form is usually silent at first, sometimes with just a dry cough or breathlessness on exertion [breathlessness · cough]
  • Disabling shortness of breath develops once the nodules merge into large fibrotic masses [breathlessness]

Signs — what you find (3)

  • Low blood oxygen on exam is common in the fast-onset, high-exposure form of the disease
  • Enlarged lymph nodes may show up on exam before any lung findings appear, especially with lower-level exposure [lymphadenopathy]
  • Most affected people have an entirely normal physical exam, so a history of dust exposure is what should raise suspicion

Tests (8)

  • There is no specific blood or lab test for this disease; diagnosis rests on exposure history plus imaging
  • Chest X-ray can show multiple nodules high in both lungs with enlarged lymph nodes at the hilum, but it can miss early disease
  • High-resolution CT picks up disease earlier and more confidently than a plain chest film
  • Small, well-defined nodules under 10 mm in the upper lobes mark the simple, uncomplicated form on imaging
  • Fused masses larger than 10 mm with irregular edges in the back-upper lung mark the complicated, fibrotic form
  • A crazy-paving pattern of ground-glass change on CT can appear in the fast-onset form
  • Breathing tests can be normal early on, later showing reduced lung volume and airflow
  • A biopsy showing whorled collagen with crystals that glow under polarized light confirms the diagnosis when imaging is unclear

If not this — what else fits (1)

  • The lung shadows of this disease can look like sarcoidosis, tuberculosis, or a lung tumor on imaging

SourceStatPearls "Silicosis" - disease-level clinical article

Presentation findings are traced to the source above.

1

STOP THE EXPOSURE, SCREEN FOR TB, REFER (RECOGNITION & REFERRAL)

1st line
Adult dose and duration

Stop further silica exposure (respirator and dust control at work, or a genuine change of job or task) and refer to pulmonology for HRCT staging and lung function testing. Screen for active and latent tuberculosis at diagnosis and periodically while exposure continues. Give pneumococcal and annual influenza vaccination. There is no drug that treats the fibrosis - the article states outright that nothing currently on offer is effective against silicosis. - Lifelong follow-up; there is no disease-modifying drug

Paediatric dose

Silicosis is an adult occupational disease from years of cumulative exposure; not applicable in children

Dose source

StatPearls: Silicosis (NCBI Bookshelf NBK594245), Treatment and Management

Why

Stop further silica exposure (respirator and dust control at work, or a genuine change of job or task) and refer to pulmonology for HRCT staging and lung function testing. Screen for active and latent tuberculosis at diagnosis and periodically while exposure continues. Give pneumococcal and annual influenza vaccination. There is no drug that treats the fibrosis - the article states outright that nothing currently on offer is effective against silicosis.

Cautions
  • Silicosis raises the risk of active tuberculosis roughly three-fold - screen for TB at diagnosis and periodically thereafter for as long as exposure continues (see Tuberculosis primary care referral for the screening/treatment pathway).
  • Refer urgently for haemoptysis, rapidly progressive breathlessness, or signs of progressive massive fibrosis or cor pulmonale.
  • Continued exposure after diagnosis accelerates progression - advice alone rarely changes this; a real change in job, task, or workplace dust control is required.
  • Simple silicosis can progress even after exposure stops, and silica exposure independently raises lung cancer and COPD risk - lifelong specialist follow-up is needed, not a one-off referral.
  • No drug row appears here because no drug treats this disease, not because it is unfinished. What the article describes is supportive care: oxygen for the hypoxic patient, the recommended vaccinations, infection treated promptly, and pulmonary rehabilitation - with lung transplantation as the mainstay once the disease reaches its end stage. Targeted drugs are not there yet: it notes that a better grasp of how silicosis does its damage points towards anti-fibrotic and anti-cytokine treatment, but that no large randomised controlled trial has yet tested any of them for effect or for safety.
  • The one drug decision that IS made here is tuberculosis chemoprophylaxis, and it belongs to the TB service. International guidance, as the article reports it, is to screen silica-exposed workers for tuberculosis and to give chemoprophylaxis where the infection is latent. The article names no drug and no dose for it, so none is printed here - see the tuberculosis entries for the regimens.
  • Stopping exposure does not stop the disease. The article is blunt: the inflammation and the damage in the lung go on advancing even after silica exposure has ceased completely. It still has to stop, because continuing accelerates it.

Prices are indicative (dataset snapshot 2026-06); verify with the pharmacy.